The Center for Biodefense Immune Modeling (CBIM) is supported by a contract with NIH/NIAID (NO1 AI 50020) with the objective of developing comprehensive, computational models of the human immune response to unmodified and genetically engineered influenza A. Dr. Hulin Wu, the biostatistician for NYICE, is the principal investigator. There is clear synergy between the goals of this center, which are to make predictions about the human immune response, and the goals of NYICE, which include the detailed measurement of the human immune response to influenza.
The Rochester Program for Biodefense of Immunocompromised Populations (RPBIP) is a recently awarded contract with NIH/NIAID (NO1 AI 50029) that concerns itself with the immune response of a variety of potentially immunocompromised groups, including those receiving TNF-alpha blockade, to vaccination. The model system used is vaccination of humans with systemic lupus erythematosus with inactivated influenza vaccine, recently the Program was requested by NIAID to propose studies to evaluate candidate H5N1 vaccines in this population as well. The goals of this program, focused on the immune response to influenza vaccine, are synergistic with NYICE and will extend the observations made by NYICE to an additional population of potentially great concern during pandemics. This Project is directed by Dr. Ignacio Sanz, and is one of only 10 such programs, nationwide.
The New Vaccine Surveillance Network (NVSN) is a cooperative agreement with the Centers for Disease Control (U01 IP000017) that builds on the extensive experience at the University of Rochester with infectious disease surveillance, particularly in children. The overall goal of this multicenter project is to monitor the impact of introduction of new vaccines by assessing vaccine utilization and disease burden before and after vaccines are recommended by ACIP and other organizations. A major focus of this activity has been on assessing the burden of influenza, as the recommendations for influenza vaccination have been gradually expanded during periods of significant vaccine shortages. The surveillance activities proposed by NYICE are similar in scope to the activities carried out by NVSN, and the expertise developed by NVSN will clearly be helpful in the clinical research proposed by NYICE. The UR NVSN is one of only four such sites, nationally.
The Human Immunology Center (HIC) is within the David H. Smith Center for Vaccine Biology and Immunology is supported by a large NIH grant, and exists to acquire, refine and develop expertise in cutting-edge techniques and to support applications in Human Immunology research. The HIC is designed with capabilities to enhance multi-disciplinary research initiatives catalyzing key clinical and basic immunology research in vaccines, HIV/AIDS, autoimmunity, allergy/asthma, transplantation as well as cancer immunology. The overall Center Director is Dr. Tim Mosmann, and the HIC Laboratory Director is Dr. Sally Quataert. The Center provides training in immunological strategies and protocols through a training program, and the goals of the Human Immunology Center are accomplished through the Human Immunology Core laboratory and also via Pilot Projects for innovative immunological research and technologies.
Get in Touch
For general questions, call:
Email: Donna Neu